HomepageCRSP • NASDAQ
add
Crispr Therapeutics AG
Vorige slotkoers
$Â 41,29
Dag-range
$Â 38,51 - $Â 40,37
Jaar-range
$Â 38,20 - $Â 91,10
Beurswaarde
3,39Â mld. USD
Gem. volume
1,79Â mln.
Koers/winst
-
Dividendrendement
-
Primaire beurs
NASDAQ
Financiële informatie
Resultatenrekening
Opbrengst
Netto inkomsten
| (USD) | sep 2024info | Wijziging j-o-j |
|---|---|---|
Opbrengst | 602,00K | — |
Bedrijfskosten | 17,42Â mln. | -4,77% |
Netto inkomsten | -85,94Â mln. | 23,37% |
Netto winstmarge | -14,28K | — |
Winst per aandeel | -1,01 | 28,37% |
EBITDA | -105,39Â mln. | 17,33% |
Effectief belastingtarief | -1,03% | — |
Balans
Totale activa
Totale passiva
| (USD) | sep 2024info | Wijziging j-o-j |
|---|---|---|
Contanten en kortetermijnbeleggingen | 1,94Â mld. | 11,26% |
Totale activa | 2,26Â mld. | 8,11% |
Totale passiva | 316,47Â mln. | -11,86% |
Totaal aandelenvermogen | 1,94 mld. | — |
Uitstaande aandelen | 85,35 mln. | — |
Koers-boekwaardeverhouding | 1,82 | — |
Rendement op activa | -11,98% | — |
Rendement op kapitaal | -12,57% | — |
Kasstroom
Nettomutatie in liquide middelen
| (USD) | sep 2024info | Wijziging j-o-j |
|---|---|---|
Netto inkomsten | -85,94Â mln. | 23,37% |
Operationele kasstroom | -106,91Â mln. | -168,25% |
Kasstroom uit beleggingen | -161,60Â mln. | -233,17% |
Kasstroom uit financiering | 9,64Â mln. | 519,54% |
Nettomutatie in liquide middelen | -258,80Â mln. | -411,81% |
Vrije kasstroom | -80,67Â mln. | -495,63% |
Over
CRISPR Therapeutics AG is a Swiss–American biotechnology company headquartered in Zug, Switzerland. It was one of the first companies formed to utilize the CRISPR gene editing platform to develop medicines for the treatment of various rare and common diseases. The company has approximately 500 employees and has offices in Zug, Switzerland, Boston, Massachusetts, San Francisco, California and London, United Kingdom. Its manufacturing facility in Framingham, Massachusetts won the Facilities of the Year Award award in 2022. The company’s lead program, exagamglogene autotemcel, or exa-cel, was granted regulatory approval by the US Food and Drug Administration in December 2023. Wikipedia
Opgericht
2013
Hoofdvestiging
Website
Werknemers
407
